Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This m...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | F&S Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666334123000107 |